SLC5A2 and type 2 diabetes mellitus: As a positive control, we confirmed the well-established effect of SGLT2 inhibition on reducing the risk of T2DM (OR = 0.66, 95% CI = 0.49 to 0.88, p = 0.005; Table S6).